Myriad Genetics (MYGN) Stock Price, News & Analysis

Company Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $5.21 to $5.38
• 50-Day Range: $3.84 to $7.70
• 52-Week Range: $3.81 to $29.30
• Volume: 907,164 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $489.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.38
• Consensus Rating: Hold

Myriad Genetics Stock Analysis - MarketRank™

Myriad Genetics scored higher than 88% of companies evaluated by MarketBeat, and ranked 122nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 10 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Myriad Genetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myriad Genetics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myriad Genetics is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myriad Genetics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.31% of the float of Myriad Genetics has been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myriad Genetics does not currently pay a dividend.

Dividend Growth

Myriad Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

9.31% of the float of Myriad Genetics has been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myriad Genetics has recently decreased by 4.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

Myriad Genetics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Myriad Genetics this week, compared to 8 articles on an average week.

Search Interest

2 people have searched for MYGN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Myriad Genetics is held by insiders.

Percentage Held by Institutions

99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYGN Stock Analysis - Frequently Asked Questions

How have MYGN shares performed this year?

Myriad Genetics' stock was trading at $13.71 at the beginning of 2025. Since then, MYGN shares have decreased by 61.3% and is now trading at $5.31.
View the best growth stocks for 2025 here.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.02. The company's quarterly revenue was down 33.6% on a year-over-year basis.
Read the conference call transcript.

Does Myriad Genetics have any subsidiaries?

Myriad Genetics subsidiaries include these companies: Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MYGN
• CIK: 899923
• Web: www.myriad.com
• Phone: (801) 584-3600
• Fax: 801-584-3640
• Employees: 2,700
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $14.38
• High Stock Price Target: $30.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +170.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.30 million
• Net Margins: -12.20%
• Pretax Margin: -15.28%
• Return on Equity: -4.95%
• Return on Assets: -3.39%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.90
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $837.60 million
• Price / Sales: 0.59
• Cash Flow: $1.01 per share
• Price / Cash Flow: 5.25
• Book Value: $7.70 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 92,180,000
• Free Float: 90,241,000
• Market Cap: $490.40 million
• Optionable: Optionable
• Beta: 1.84